Height, selected genetic markers and prostate cancer risk: Results from the PRACTICAL consortium

Artitaya Lophatananon; Sarah Stewart-Brown; Zsofia Kote-Jarai; Ali Amin Al Olama; Sara Benlloch Garcia; David E. Neal; Freddie C. Hamdy; Jenny L. Donovan; Graham G. Giles; Liesel M. Fitzgerald; APCB BioResource; The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium; Jyotsna Batra

doi:10.1038/bjc.2017.231

Height, selected genetic markers and prostate cancer risk: Results from the PRACTICAL consortium

Artitaya Lophatananon, Sarah Stewart-Brown, Zsofia Kote-Jarai, Ali Amin Al Olama, Sara Benlloch Garcia, David E. Neal, Freddie C. Hamdy, Jenny L. Donovan, Graham G. Giles, Liesel M. Fitzgerald, APCB BioResource, The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, Jyotsna Batra

Research output: Contribution to journal › Article › Research › peer-review

Abstract

Background:
Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer.

Methods:
We analysed data from the PRACTICAL consortium consisting of 6207 prostate cancer cases and 6016 controls and a subset of high grade cases (2480 cases). We explored height, polymorphisms in genes related to growth processes as main effects and their possible interactions.

Results:
The results suggest that height is associated with high-grade prostate cancer risk. Men with height >180 cm are at a 22% increased risk as compared to men with height <173 cm (OR 1.22, 95% CI 1.01–1.48). Genetic variants in the growth pathway gene showed an association with prostate cancer risk. The aggregate scores of the selected variants identified a significantly increased risk of overall prostate cancer and high-grade prostate cancer by 13% and 15%, respectively, in the highest score group as compared to lowest score group.

Conclusions:
There was no evidence of gene-environment interaction between height and the selected candidate SNPs.Our findings suggest a role of height in high-grade prostate cancer. The effect of genetic variants in the genes related to growth is seen in all cases and high-grade prostate cancer. There is no interaction between these two exposures.

Original language	English
Pages (from-to)	734-743
Number of pages	10
Journal	British Journal of Cancer
Volume	117
Issue number	5
DOIs	https://doi.org/10.1038/bjc.2017.231
Publication status	Published - 22 Aug 2017
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.2017.231Licence: CC BY

Height, selected genetic markers and prostate cancer risk Results from the PRACTICAL consortiumFinal published version, 409 KBLicence: CC BY

Cite this

Lophatananon, A., Stewart-Brown, S., Kote-Jarai, Z., Olama, A. A. A., Garcia, S. B., Neal, D. E., Hamdy, F. C., Donovan, J. L., Giles, G. G., Fitzgerald, L. M., APCB BioResource, The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, & Batra, J. (2017). Height, selected genetic markers and prostate cancer risk: Results from the PRACTICAL consortium. British Journal of Cancer, 117(5), 734-743. https://doi.org/10.1038/bjc.2017.231

@article{3c8c6e38d49e4308822c824f36b26d2d,

title = "Height, selected genetic markers and prostate cancer risk: Results from the PRACTICAL consortium",

abstract = "Background:Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer.Methods:We analysed data from the PRACTICAL consortium consisting of 6207 prostate cancer cases and 6016 controls and a subset of high grade cases (2480 cases). We explored height, polymorphisms in genes related to growth processes as main effects and their possible interactions.Results:The results suggest that height is associated with high-grade prostate cancer risk. Men with height >180 cm are at a 22% increased risk as compared to men with height <173 cm (OR 1.22, 95% CI 1.01–1.48). Genetic variants in the growth pathway gene showed an association with prostate cancer risk. The aggregate scores of the selected variants identified a significantly increased risk of overall prostate cancer and high-grade prostate cancer by 13% and 15%, respectively, in the highest score group as compared to lowest score group.Conclusions:There was no evidence of gene-environment interaction between height and the selected candidate SNPs.Our findings suggest a role of height in high-grade prostate cancer. The effect of genetic variants in the genes related to growth is seen in all cases and high-grade prostate cancer. There is no interaction between these two exposures.",

author = "Artitaya Lophatananon and Sarah Stewart-Brown and Zsofia Kote-Jarai and Olama, {Ali Amin Al} and Garcia, {Sara Benlloch} and Neal, {David E.} and Hamdy, {Freddie C.} and Donovan, {Jenny L.} and Giles, {Graham G.} and Fitzgerald, {Liesel M.} and {APCB BioResource} and {The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium} and Southey, {Melissa C.} and Paul Pharoah and Nora Pashayan and Henrik Gronberg and Markus Aly and Stanford, {Janet L.} and Hermann Brenner and Dieffenbach, {Aida K.} and Volker Arndt and Park, {Jong Y.} and Lin, {Hui Yi} and Thomas Sellers and Chavdar Slavov and Radka Kaneva and Vanio Mitev and Jyotsna Batra and Amanda Spurdle and Clements, {Judith A.} and Douglas Easton and Eeles, {Rosalind A.} and Kenneth Muir and Johanna Schleutker and Nordestgaard, {B{\o}rge G.} and Fredrik Wiklund and Travis, {Ruth C.} and Haiman, {Christopher A.} and Thibodeau, {Stephen N.} and Christiane Maier and Vogel Walther and Blot, {William J.} and Kibel, {Adam S.} and Cezary Cybulski and Lisa Cannon-Albright and Hardev Pandha and Teixeira, {Manuel R.} and Margaret Cook and Koveela Govindasami and Michelle Guy and Daniel Leongamornlert and Sawyer, {Emma J.} and Rosemary Wilkinson and Angela Morgan and Cyril Fisher and Saunders, {Edward J.} and Malgorzata Tymrakiewicz and Naomi Livni and Steve Hazel and Tokhir Dadaev and Angela Cox and Anne George and Athene Lane and Gemma Marsden and Michael Davis and Paul Brown and John Pedersen and Hopper, {John L.} and Ami Karlsson and Carin Cavalli-Bjoerkman and Jan Adolfson and Johansson, {Jan Erik} and Michael Broms and Paer Stattin and Suzanne Kolb and Christa Stegmaier and Babu Zachariah and Hyun Park and James Haley and Julio Pow-Sang and Maria Rincon and Selina Radlein and Aleksandrina Vlahova and Atanaska Mitkova and Darina Kachakova and Elenko Popov and Svetlana Christova and Tihomir Dikov and Allison Eckert and Angus Collins and Glenn Wood and Greg Malone and Kimberly Alexander and Kris Kerr and Kedda, {Mary Anne} and Megan Turner and Pamela Saunders and Peter Heathcote and Srilakshmi Srinivasan and Tracy Omara and Trina Yeadon and Felicity Lose",

year = "2017",

month = aug,

day = "22",

doi = "10.1038/bjc.2017.231",

language = "English",

volume = "117",

pages = "734--743",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "5",

}

Lophatananon, A, Stewart-Brown, S, Kote-Jarai, Z, Olama, AAA, Garcia, SB, Neal, DE, Hamdy, FC, Donovan, JL, Giles, GG, Fitzgerald, LM, APCB BioResource, The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium & Batra, J 2017, 'Height, selected genetic markers and prostate cancer risk: Results from the PRACTICAL consortium', British Journal of Cancer, vol. 117, no. 5, pp. 734-743. https://doi.org/10.1038/bjc.2017.231

TY - JOUR

T1 - Height, selected genetic markers and prostate cancer risk: Results from the PRACTICAL consortium

AU - Lophatananon, Artitaya

AU - Stewart-Brown, Sarah

AU - Kote-Jarai, Zsofia

AU - Olama, Ali Amin Al

AU - Garcia, Sara Benlloch

AU - Neal, David E.

AU - Hamdy, Freddie C.

AU - Donovan, Jenny L.

AU - Giles, Graham G.

AU - Fitzgerald, Liesel M.

AU - APCB BioResource

AU - The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium

AU - Southey, Melissa C.

AU - Pharoah, Paul

AU - Pashayan, Nora

AU - Gronberg, Henrik

AU - Aly, Markus

AU - Stanford, Janet L.

AU - Brenner, Hermann

AU - Dieffenbach, Aida K.

AU - Arndt, Volker

AU - Park, Jong Y.

AU - Lin, Hui Yi

AU - Sellers, Thomas

AU - Slavov, Chavdar

AU - Kaneva, Radka

AU - Mitev, Vanio

AU - Batra, Jyotsna

AU - Spurdle, Amanda

AU - Clements, Judith A.

AU - Easton, Douglas

AU - Eeles, Rosalind A.

AU - Muir, Kenneth

AU - Schleutker, Johanna

AU - Nordestgaard, Børge G.

AU - Wiklund, Fredrik

AU - Travis, Ruth C.

AU - Haiman, Christopher A.

AU - Thibodeau, Stephen N.

AU - Maier, Christiane

AU - Walther, Vogel

AU - Blot, William J.

AU - Kibel, Adam S.

AU - Cybulski, Cezary

AU - Cannon-Albright, Lisa

AU - Pandha, Hardev

AU - Teixeira, Manuel R.

AU - Cook, Margaret

AU - Govindasami, Koveela

AU - Guy, Michelle

AU - Leongamornlert, Daniel

AU - Sawyer, Emma J.

AU - Wilkinson, Rosemary

AU - Morgan, Angela

AU - Fisher, Cyril

AU - Saunders, Edward J.

AU - Tymrakiewicz, Malgorzata

AU - Livni, Naomi

AU - Hazel, Steve

AU - Dadaev, Tokhir

AU - Cox, Angela

AU - George, Anne

AU - Lane, Athene

AU - Marsden, Gemma

AU - Davis, Michael

AU - Brown, Paul

AU - Pedersen, John

AU - Hopper, John L.

AU - Karlsson, Ami

AU - Cavalli-Bjoerkman, Carin

AU - Adolfson, Jan

AU - Johansson, Jan Erik

AU - Broms, Michael

AU - Stattin, Paer

AU - Kolb, Suzanne

AU - Stegmaier, Christa

AU - Zachariah, Babu

AU - Park, Hyun

AU - Haley, James

AU - Pow-Sang, Julio

AU - Rincon, Maria

AU - Radlein, Selina

AU - Vlahova, Aleksandrina

AU - Mitkova, Atanaska

AU - Kachakova, Darina

AU - Popov, Elenko

AU - Christova, Svetlana

AU - Dikov, Tihomir

AU - Eckert, Allison

AU - Collins, Angus

AU - Wood, Glenn

AU - Malone, Greg

AU - Alexander, Kimberly

AU - Kerr, Kris

AU - Kedda, Mary Anne

AU - Turner, Megan

AU - Saunders, Pamela

AU - Heathcote, Peter

AU - Srinivasan, Srilakshmi

AU - Omara, Tracy

AU - Yeadon, Trina

AU - Lose, Felicity

PY - 2017/8/22

Y1 - 2017/8/22

N2 - Background:Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer.Methods:We analysed data from the PRACTICAL consortium consisting of 6207 prostate cancer cases and 6016 controls and a subset of high grade cases (2480 cases). We explored height, polymorphisms in genes related to growth processes as main effects and their possible interactions.Results:The results suggest that height is associated with high-grade prostate cancer risk. Men with height >180 cm are at a 22% increased risk as compared to men with height <173 cm (OR 1.22, 95% CI 1.01–1.48). Genetic variants in the growth pathway gene showed an association with prostate cancer risk. The aggregate scores of the selected variants identified a significantly increased risk of overall prostate cancer and high-grade prostate cancer by 13% and 15%, respectively, in the highest score group as compared to lowest score group.Conclusions:There was no evidence of gene-environment interaction between height and the selected candidate SNPs.Our findings suggest a role of height in high-grade prostate cancer. The effect of genetic variants in the genes related to growth is seen in all cases and high-grade prostate cancer. There is no interaction between these two exposures.

AB - Background:Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer.Methods:We analysed data from the PRACTICAL consortium consisting of 6207 prostate cancer cases and 6016 controls and a subset of high grade cases (2480 cases). We explored height, polymorphisms in genes related to growth processes as main effects and their possible interactions.Results:The results suggest that height is associated with high-grade prostate cancer risk. Men with height >180 cm are at a 22% increased risk as compared to men with height <173 cm (OR 1.22, 95% CI 1.01–1.48). Genetic variants in the growth pathway gene showed an association with prostate cancer risk. The aggregate scores of the selected variants identified a significantly increased risk of overall prostate cancer and high-grade prostate cancer by 13% and 15%, respectively, in the highest score group as compared to lowest score group.Conclusions:There was no evidence of gene-environment interaction between height and the selected candidate SNPs.Our findings suggest a role of height in high-grade prostate cancer. The effect of genetic variants in the genes related to growth is seen in all cases and high-grade prostate cancer. There is no interaction between these two exposures.

UR - http://www.scopus.com/inward/record.url?scp=85028312750&partnerID=8YFLogxK

U2 - 10.1038/bjc.2017.231

DO - 10.1038/bjc.2017.231

M3 - Article

C2 - 28765617

AN - SCOPUS:85028312750

SN - 0007-0920

VL - 117

SP - 734

EP - 743

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 5

ER -

Height, selected genetic markers and prostate cancer risk: Results from the PRACTICAL consortium

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Erratum: Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium

Cite this

Height, selected genetic markers and prostate cancer risk: Results from the PRACTICAL consortium

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Related Research Outputs

Erratum: Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium

Cite this